Emerging Roles for Intersectin (ITSN) in Regulating Signaling and Disease Pathways

被引:38
作者
Hunter, Michael P. [1 ]
Russo, Angela [1 ]
O'Bryan, John P. [1 ]
机构
[1] Univ Illinois, Cardiovasc Res Ctr, Ctr Canc, Dept Pharmacol, Chicago, IL 60612 USA
基金
美国国家卫生研究院;
关键词
Intersectin; endocytosis; cell signaling; Ras; PI3KC2; beta; Down Syndrome; Alzheimer Disease; cancer; neuroblastoma; glioblastoma; DENDRITIC SPINE DEVELOPMENT; CLATHRIN-MEDIATED ENDOCYTOSIS; ASYMMETRIC CELL-DIVISION; GROWTH-FACTOR RECEPTOR; CDC42 GEF INTERSECTIN; ADAPTER PROTEIN; ALZHEIMERS-DISEASE; DOWN-SYNDROME; FORMS; EPS15; HOMOLOGY;
D O I
10.3390/ijms14047829
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Intersectins (ITSNs) represent a family of multi-domain adaptor proteins that regulate endocytosis and cell signaling. ITSN genes are highly conserved and present in all metazoan genomes examined thus far. Lower eukaryotes have only one ITSN gene, whereas higher eukaryotes have two ITSN genes. ITSN was first identified as an endocytic scaffold protein, and numerous studies reveal a conserved role for ITSN in endocytosis. Subsequently, ITSNs were found to regulate multiple signaling pathways including receptor tyrosine kinases (RTKs), GTPases, and phosphatidylinositol 3-kinase Class 2beta (PI3KC2 beta). ITSN has also been implicated in diseases such as Down Syndrome (DS), Alzheimer Disease (AD), and other neurodegenerative disorders. This review summarizes the evolutionary conservation of ITSN, the latest research on the role of ITSN in endocytosis, the emerging roles of ITSN in regulating cell signaling pathways, and the involvement of ITSN in human diseases such as DS, AD, and cancer.
引用
收藏
页码:7829 / 7852
页数:24
相关论文
共 118 条
[1]  
Adams A, 2000, J BIOL CHEM, V275, P27414
[2]   The Minimal Autoinhibited Unit of the Guanine Nucleotide Exchange Factor Intersectin [J].
Ahmad, K. Farid ;
Lim, Wendell A. .
PLOS ONE, 2010, 5 (06)
[3]   Zebrafish hox clusters and vertebrate genome evolution [J].
Amores, A ;
Force, A ;
Yan, YL ;
Joly, L ;
Amemiya, C ;
Fritz, A ;
Ho, RK ;
Langeland, J ;
Prince, V ;
Wang, YL ;
Westerfield, M ;
Ekker, M ;
Postlethwait, JH .
SCIENCE, 1998, 282 (5394) :1711-1714
[4]   The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity [J].
Anastasi, S. ;
Baietti, M. F. ;
Frosi, Y. ;
Alema, S. ;
Segatto, O. .
ONCOGENE, 2007, 26 (57) :7833-7846
[5]   Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin [J].
Anastasi, S ;
Sala, G ;
Chen, HP ;
Caprini, E ;
Russo, G ;
Iacovelli, S ;
Lucini, F ;
Ingvarsson, S ;
Segatto, O .
ONCOGENE, 2005, 24 (28) :4540-4548
[6]   MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].
Armstrong, SA ;
Staunton, JE ;
Silverman, LB ;
Pieters, R ;
de Boer, ML ;
Minden, MD ;
Sallan, SE ;
Lander, ES ;
Golub, TR ;
Korsmeyer, SJ .
NATURE GENETICS, 2002, 30 (01) :41-47
[7]   Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses [J].
Blalock, EM ;
Geddes, JW ;
Chen, KC ;
Porter, NM ;
Markesbery, WR ;
Landfield, PW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (07) :2173-2178
[8]  
Boller D, 2012, ANTICANCER RES, V32, P3015
[9]   GENETIC CHANGES IN SKIN TUMOR PROGRESSION - CORRELATION BETWEEN PRESENCE OF A MUTANT RAS GENE AND LOSS OF HETEROZYGOSITY ON MOUSE CHROMOSOME-7 [J].
BREMNER, R ;
BALMAIN, A .
CELL, 1990, 61 (03) :407-417
[10]   National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001 [J].
Canfield, Mark A. ;
Honein, Margaret A. ;
Yuskiv, Nataliya ;
Xing, Jian ;
Mai, Cara T. ;
Collins, Julianne S. ;
Devine, Owen ;
Petrini, Joann ;
Ramadhani, Tunu A. ;
Hobbs, Charlotte A. ;
Kirby, Russell S. .
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2006, 76 (11) :747-756